In earlier biopsy-based studies, however, treatment effect of ACEIs/ARBs against angiotensin II, which has been regarded as playing a major role in the progression of nephrosclerosis [16], was not examined through risk analysis of renal outcomes. The gene discussed is AGT; the disease is nephrosclerosis.